BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML

BACKGROUND: Activating mutations of Fms-like tyrosine kinase 3 (FLT3) constitute a major driver in the pathogenesis of acute myeloid leukaemia (AML). Hence, pharmacological inhibitors of FLT3 are of therapeutic interest for AML. METHODS: The effects of inhibition of FLT3 activity by a novel potent F...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, W-H, Jiaang, W-T, Chen, C-W, Yen, K-J, Hsieh, S-Y, Yen, S-C, Chen, C-P, Chang, K-Y, Chang, C-Y, Chang, T-Y, Huang, Y-L, Yeh, T-K, Chao, Y-S, Chen, C-T, Hsu, J T-A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273346/
https://www.ncbi.nlm.nih.gov/pubmed/22187040
http://dx.doi.org/10.1038/bjc.2011.564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273346/
https://www.ncbi.nlm.nih.gov/pubmed/22187040
http://dx.doi.org/10.1038/bjc.2011.564

Ejemplares similares